Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. reports developments tied to computerized drug delivery instruments for dental and medical applications. The company’s Dynamic Pressure Sensing technology supports pressure-guided injection and fluid-aspiration procedures, including dental anesthesia delivery through The Wand STA system and medical applications such as CompuFlo for controlled epidural injections.
Recurring news themes include financial results, business-update calls, commercialization programs, physician and dental-practice adoption, distributor and reimbursement infrastructure, international product registrations, disposable utilization, operating expense initiatives, and capital actions involving common stock and warrants.
Milestone Scientific (NYSE: MLSS) reported second quarter 2026 revenue of $2.84 million, up 22% year-over-year, with medical segment revenue rising approximately 231% on strong CompuFlo adoption. Six-month revenue grew 9.8% to $5.0 million.
Q2 gross margin was 67.2% versus 69.6% a year ago, reflecting product mix and higher costs, including tariffs. Operating expenses fell 4.2% to $3.0 million, narrowing the net loss to $1.06 million ($0.01 per share) from $1.48 million. For the first half, operating expenses declined 20.5% and net loss improved to $1.9 million ($0.02 per share).
As of June 30, 2026, cash and cash equivalents were $2.07 million, with working capital of $3.7 million and $466,000 in convertible debt. The company reaffirmed 2026 revenue guidance of $9.8–$10.2 million, expecting double-digit growth and faster expansion in CompuFlo sales.
Milestone Scientific (NYSE: MLSS) will hold a conference call at 8:30 AM Eastern Time on Friday, August 14, 2026, to discuss second quarter 2026 financial results, corporate progress and other developments. Investors can join via toll-free and international phone lines or live webcast, with an audio replay available through August 28, 2026.
Milestone Scientific (NYSE American: MLSS) has entered a strategic distribution agreement with Red One Medical, a federal healthcare distributor serving the U.S. Department of Veterans Affairs (VA), Department of Defense (DoD), Defense Health Agency (DHA), Indian Health Service (IHS) and other federal healthcare organizations. Red One Medical will market, distribute and support Milestone Scientific’s CompuFlo® Epidural System and related disposable products through its federal sales organization and government contracting infrastructure.
The partnership is intended to expand commercial access to CompuFlo across VA medical centers, military treatment facilities and other eligible federal facilities, which together serve more than 18 million enrolled Veterans and military beneficiaries. According to Milestone Scientific, the collaboration may accelerate awareness, product evaluations and commercial opportunities in the federal channel, but the agreement does not guarantee contract awards, evaluations, purchase orders or adoption by any federal agency or facility. CompuFlo is a computer-controlled epidural injection system using Dynamic Pressure Sensing technology and has received 510(k) clearance from the U.S. Food and Drug Administration.
Milestone Scientific (NYSE American: MLSS) launched the first phase of its AI strategy with the pilot debut of Milo, an AI-enabled digital engagement platform, at the American Society of Pain and Neuroscience (ASPN) Annual Conference in Miami Beach, July 16–18, 2026. Milo is designed to complement Milestone’s precision drug delivery and Dynamic Pressure Sensing technologies by delivering intelligent digital engagement, enhanced customer support and scalable commercial operations. Initially, Milo will answer common product questions, provide education, collect customer information, assist with lead qualification and connect healthcare professionals with sales, clinical and support teams.
According to Milestone Scientific, Milo is the first step in a broader AI roadmap built around four initiatives: customer engagement, commercial excellence, clinical innovation and a connected MedTech platform that integrates devices, software, data and AI. The company will use feedback from the ASPN 2026 pilot to direct future Milo and AI development.
Milestone Scientific (NYSE: MLSS) announced preliminary, unaudited Q2 2026 revenue of approximately $2.8M, up about 21% YoY, and 1H 2026 revenue of about $5.0M, up 9% YoY.
The medical segment is expected to deliver 300% revenue growth versus Q2 2025, supported by progress in reimbursement claims, while international dental markets continue to expand. Final Q2 2026 results are expected in August 2026.
Milestone Scientific (NYSE: MLSS) announced governance changes to support its next phase of growth. Benedetta I. Casamento moves from Chair to Executive Chair, working more closely with management on strategy and execution.
The company appointed Greg Shilling and Kelly Ann Ulto as independent directors and restructured its agreement with founder Leonard “Len” Osser, who will continue as an advisor. Further details appear in a Form 8-K.
Milestone Scientific (NYSE American: MLSS) reported growing clinical adoption and physician acceptance of its CompuFlo Epidural System, supported by a new University of Texas Medical Branch study in Operative Neurosurgery.
The study found CompuFlo-guided spinal cord stimulator implantation was associated with a 91% reduction in odds of composite complications versus traditional loss-of-resistance techniques.
Milestone Scientific (NYSE:MLSS) reported Q1 2026 revenue of $2.16 million, slightly below $2.23 million in Q1 2025. Gross profit was $1.56 million with a 72.3% margin. Operating loss improved to $828,000 from $2.0 million as operating expenses fell over 30%.
Net loss was $840,000 ($0.01 per share). Medical segment revenue more than doubled year-over-year. As of March 31, 2026, cash was $1.2 million. A subsequent private placement raised $2.15 million. Management reaffirmed 2026 revenue guidance of $9.8–$10.2 million and continues to target cash flow breakeven in early 2027, while substantial doubt about going concern status remains.
Milestone Scientific (NYSE: MLSS) will host a conference call at 8:30 AM ET on May 14, 2026 to discuss first-quarter 2026 financial results, corporate progress, and other developments. Dial-in numbers, access codes, a live webcast and replay are provided; the audio replay is available through May 28, 2026.
Webcast: https://www.webcaster5.com/Webcast/Page/2306/53997. U.S. dial-in: 888-506-0062; international: +1 973-528-0011; access code: 950491. Replay dial-in access code: 53997.
Milestone Scientific (NYSE: MLSS) reported expansion of its CompuFlo® medical business, launching an Advisor Program in February 2026 and initiating procedural use across multiple Medicare Administrative Contractor jurisdictions and select commercial payers.
The program is active in NJ, FL, PA, NY, TN, TX, and GA, with Noridian and NGS expansion underway. Milestone reports active epidural procedures, initial case submissions to payers, growing sales consultant coverage, and academic collaborations. CompuFlo® retains CPT Category III code 0777T; Category I progression is not assured.